Merus NV (NASDAQ:MRUS) hit a new 52-week high during trading on Friday . The company traded as high as $10.89 and last traded at $10.54, with a volume of 20,268 shares changing hands. The stock had previously closed at $8.50.

A number of equities research analysts have recently commented on the company. Wedbush assumed coverage on Merus NV in a research report on Monday, June 13th. They set an “outperform” rating and a $14.00 price objective for the company. Jefferies Group reiterated a “buy” rating and set a $19.00 price objective on shares of Merus NV in a research report on Wednesday, July 13th. Citigroup Inc. assumed coverage on Merus NV in a research report on Monday, June 13th. They set a “buy” rating and a $14.00 price objective for the company. Finally, Guggenheim assumed coverage on Merus NV in a research report on Monday, June 13th. They set a “buy” rating and a $18.00 price objective for the company.

The firm’s market capitalization is $90.93 million. The stock’s 50 day moving average price is $8.36 and its 200-day moving average price is $8.63.

Merus BV is a biotechnology company based in the Netherlands. It develops therapeutic monoclonal antibodies that address multiple targets in the treatment of cancer. The Company’s technology base includes transgenic MeMo mouse, which produces therapeutic human antibodies. The technologies are used to create the Company’s products, notably Biclonics, antibodies used for the treatment of tumors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.